Table 2.
Base-case results
| 3 months | 12 months | |||
|---|---|---|---|---|
| Tisagenlecleucel | Blinatumomab | Tisagenlecleucel | Blinatumomab | |
| Outcomes (discounted) | ||||
| Discounted LYs | 7.13 | 1.80 | 7.35 | 1.80 |
| Discounted QALYs | 5.36 | 1.09 | 5.53 | 1.09 |
| Costs (discounted) | ||||
| Tisagenlecleucela | $385,667 | $385,668 | $0 | |
| Blinatumomaba | $24,710 | $145,355 | $24,710 | $145,355 |
| IVIg | $23,841 | $4,382 | $21,981 | $4,382 |
| EFS | $41,217 | $7,128 | $42,602 | $7,128 |
| PD | $97,787 | $49,429 | $100,229 | $49,429 |
| SCTb | $12,667 | $31,636 | $0 | |
| Total discounted | $585,890 | $206,294 | $606,825 | $206,294 |
| Incremental | ||||
| Discounted costs | $379,595 | $400,532 | ||
| Discounted LYs | 5.32 | 5.55 | ||
| Discounted QALYs | 4.27 | 4.44 | ||
| ICER | ||||
| Cost/LY | $71,318 | $72,206 | ||
| Cost/QALY | $88,979 | $90,129 | ||
EFS event-free survival, ICER incremental cost-effectiveness ratio, IVIg intravenous immunoglobulin, LY life year, PD progressive disease, QALY quality-adjusted life year, SCT stem cell transplant
aAncillary costs
bCost of SCT not considered separately in the blinatumomab arm of the model but was included in the total cost of blinatumomab